ZBH · Q2 2025 Earnings
BullishZimmer Biomet
Reported August 7, 2025
30-second summary
Zimmer Biomet delivered Q2 revenue of $2.08B (+7% YoY) and non-GAAP EPS of $2.07, and used the print to tighten FY25 reported revenue growth guidance to 6.7–7.7% and raise adjusted EPS guidance to $8.10–$8.30. The more important signal is qualitative: management called July the strongest month of 2025 so far, cut the tariff headwind from $60–80M to ~$40M, and flipped FX from a hedge to a 50bps tailwind. Conviction on second-half acceleration moved from forecast to observed.
Headline numbers
EPS
Q2 FY2025
$2.07
Revenue
Q2 FY2025
$2.08B
+7.0% YoY
Operating margin
Q2 FY2025
14.4%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $2.08B | +7.0% |
| EPS | $2.07 | — |
| Operating margin | 14.4% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Knees | $0.826B | +3.1% |
| Hips | $0.536B | +5.8% |
| S.E.T. | $0.551B | +17.3% |
| Technology & Data, Bone Cement and Surgical | $0.165B | -0.2% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| United States | $1.174B | +6.1% |
| International | $0.904B | +8.1% |
| Organic Constant Currency Revenue Growth | 2.8% | — |
| Constant Currency Revenue Growth | 5.4% | — |
| Adjusted Diluted EPS Growth | 3.0% | — |
Management tone
Zimmer Biomet typically uses measured, hedged language. This quarter the posture sharpened materially around a single thesis: second-half acceleration is no longer a forecast but an observation. Management repeated "our confidence in the second half revenue growth expectation for the year is very high" three times in prepared remarks — a degree of verbatim repetition that is itself the signal.
The most consequential new disclosure is real-time July color. Management explicitly named July "the strongest month so far in the year 2025" with "upper single-digit U.S. growth," and used that data point to validate the H2 ramp rather than ask investors to trust the pipeline narrative. Last quarter the H2 acceleration depended on Magnificent Seven product launches landing; this quarter the launches are landing and the print is showing it.
The macro overhang got smaller in three distinct ways simultaneously. Tariff exposure dropped from $60–80M to ~$40M through mitigation. FX flipped from neutral/headwind to +50bps tailwind. Operating margin compression was narrowed from -100/-150bps to -100bps. Each is incremental; together they explain how EPS guidance is being raised in a year that absorbs Paragon 28 dilution.
CEO language went beyond operational confidence: "I have more conviction in our strategy and team than ever." Personal-conviction phrasing is rare on a Zimmer call and reads as deliberate signaling rather than off-script enthusiasm — particularly paired with the Q&A disclosure of long-term targets (5% organic growth by end of 2027, 6–7% by end of 2030) that frame the Monogram and Paragon 28 deals as diversification toward higher-growth surgical adjacencies.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Robbie Marcus · J.P. Morgan
Breakdown of drivers for organic sales growth guide acceleration in H2 2025, level of confidence and visibility, and Q3 vs Q4 cadence expectations.
Management provided detailed mathematical drivers: 100 bps from day rate headwind elimination, 100 bps from ERP comparison, strong July performance (upper single-digit U.S. growth), NEIS acceleration of 150 bps sequentially, and 50-60 bps from emerging markets distributor order shift. Q3 expected to scratch 6% organic growth; Q4 expected slightly lower.
David Roman · Goldman Sachs
Clarification on end market trends in orthopedics, context for July strength relative to broader market health, and whether markets are slowing.
Management emphasized overall market remains healthy, above pre-COVID levels though below post-COVID peaks. June was short, but May, April, and July were very strong. Pricing favorable at 20 bps positive in quarter. Case volumes strong across inpatient, outpatient, HOPD, and ASCs. Waiting lists 4-6 months at large centers. Market expected to grow at least 4% with no horizon evidence of slowdown.
Jason Wittes · Roth Capital
Monogram competitive positioning versus Mako/Stryker, intellectual property advantages, and capabilities in autonomous functionality and procedure time reduction.
Management explained Monogram's semi-autonomous and fully autonomous capabilities differentiate from competitors. Key features: 7-degree dynamic robotic arm avoiding patella cutting, robotic control saw preventing burring, AI/ML personalization, marker-less tracking, and fully remote surgery capability. Semi-autonomous launch early 2027; company hiring aggressively and conducting extensive clinical work.
Larry Beagleson · Wells Fargo
Elaboration on podcast comments regarding need to diversify ZBH, rethinking capital allocation strategy, and implications for M&A going forward.
Management clarified innovation gaps have been resolved across portfolio (NEIS, HIPS, knees, robotics/navigation). Future focus is diversification to achieve 5% organic growth by end of 2027 and 6-7% by end of 2030. Capital allocation evolved but not changed; pursuing responsible M&A in transformational spaces, not just current spaces. Cited Monogram and Paragon 28 as examples of problem-solving deals.
Vijay Kumar · Evercore ISI
Bridge analysis on operating margin expansion of 50 bps, despite 100 bps YoY decline, and impact of tariffs, Paragon acquisition, Monogram, and FX on margins.
Management attributed margin expansion to: tariff headwind improvement ($40M vs. original $60-80M estimate) due to mitigation and lower rates, better-than-expected free cash flow reducing interest expense by ~$10M, operational improvements continuing, and modest FX benefit. EPS guidance back to original levels despite Paragon and Monogram acquisitions and tariff headwinds. Paragon 28 margin accretion delayed due to integration timing.
What to watch into next quarter
Does Q3 organic constant currency growth print at or above 6%? Management explicitly guided to "scratch 6%" — anything below would undermine the H2 acceleration narrative that is now the primary thesis. The 50–60bps distributor-order benefit is included in that number, so a clean ~5.4% ex-distributor is the real bar.
Knees recovery trajectory. +3.1% YoY in Q2 is the slowest core franchise. Management says the Magnificent Seven launches address this; watch whether Knees closes the gap to Hips (+5.8%) in Q3 or stays the laggard.
Tariff figure stability around $40M. Management cut from $60–80M to ~$40M this quarter. Any drift back up would compress the EPS raise.
Magnificent Seven product cycle traction — qualitative confirmation. Management staked credibility on this launch driving acceleration "in the back half of 2025 and beyond." Watch for specific revenue contribution disclosure or unit metrics on the Q3 call.
Monogram integration milestones. Semi-autonomous launch targeted early 2027; regulatory progress updates and trial enrollment beyond the current 100+ patients are the near-term checkpoints.
Sources
- Zimmer Biomet Q2 2025 Press Release (SEC EX-99.1): https://www.sec.gov/Archives/edgar/data/1136869/000095017025104527/zbh-ex99_1.htm
- Q2 2025 earnings call prepared remarks and Q&A (referenced via extraction; live transcript unavailable at time of writing)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.